{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:48:18Z","timestamp":1785746898256,"version":"3.56.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The BEAM regimen (carmustine, etoposide, cytarabine, melphalan) is the standard conditioning regimen for autologous hematopoietic stem cell transplantation (auto-HSCT) in diffuse large B-cell lymphoma (DLBCL). Due to global carmustine shortages, bendamustine-based BeEAM has been proposed as an alternative. This study compared clinical outcomes between BEAM and BeEAM regimens in DLBCL patients undergoing auto-HSCT. A retrospective analysis of 60 consecutive DLBCL patients undergoing auto-HSCT (2019\u20132024) was conducted. Patients received either BEAM (n=45) or BeEAM (n=15) conditioning. Endpoints included progression-free survival (PFS), overall survival (OS), and treatment response. Survival outcomes were analyzed using the Kaplan-Meier method and the log-rank test. The BEAM group demonstrated significantly superior 3-year PFS (88.7% vs. 75.8%, p=0.024) and OS (95.3% vs. 68.9%, p=0.017) compared to BeEAM. In consolidation patients (n=50), BEAM showed numerically better PFS (89.5% vs. 81.8%, p=0.25) and OS (94.5% vs. 80.8%, p=0.069). Among patients with a pre-transplant complete response (n=52), BEAM showed significantly improved 3-year OS (94.2% vs. 68.9%, p=0.04) and numerically better PFS (86.1% vs. 75.8%, p=0.059). All patients engrafted successfully with comparable neutrophil and platelet recovery. The complete response rate improved from 86.7% (52\/60) pre-transplant to 100% (60\/60) post-transplant. In summary, BEAM may be associated with better outcomes than BeEAM in this cohort. However, due to the limited sample size, these findings should be interpreted as exploratory, and larger prospective studies are needed to validate these observations.<\/jats:p>","DOI":"10.3389\/fonc.2026.1730912","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:31:25Z","timestamp":1785745885000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of BEAM versus BeEAM conditioning regimens in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: a retrospective single-center study"],"prefix":"10.3389","volume":"16","author":[{"given":"Saibiya","family":"Akebaer","sequence":"first","affiliation":[{"name":"Hematology Center, the First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[{"name":"Hematology Center, the First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"Xu","sequence":"additional","affiliation":[{"name":"Hematology Center, the First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaile","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hematology Center, the First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixue","family":"Yang","sequence":"additional","affiliation":[{"name":"Hematology Center, the First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Han","sequence":"additional","affiliation":[{"name":"Hematology Center, the First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Hou","sequence":"additional","affiliation":[{"name":"Hematology Center, the First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Jiang","sequence":"additional","affiliation":[{"name":"Hematology Center, the First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Hematology Center, the First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1177\/09636897231179364","article-title":"Beeam (Bendamustine, Etoposide, Cytarabine, Melphalan) versus Beam (Carmustine, Etoposide, Cytarabine, Melphalan) as conditioning regimen before autologous haematopoietic cell transplantation: A systematic review and meta-analysis","volume":"32","author":"Wu","year":"2023","journal-title":"Cell Transplant"},{"key":"B2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jtct.2022.05.003","article-title":"Evaluation of melphalan exposure in lymphoma patients undergoing Beam and autologous hematopoietic cell transplantation","volume":"28","author":"Dahi","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5114\/wo.2018.77046","article-title":"Comparable safety profile of Beeam (Bendamustine, Etoposide, Cytarabine, Melphalan) and Beam (Carmustine, Etoposide, Cytarabine, Melphalan) as conditioning before autologous haematopoietic cell transplantation","volume":"22","author":"Frankiewicz","year":"2018","journal-title":"Contemp Oncol (Pozn)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"34.e1","DOI":"10.1016\/j.jtct.2022.10.003","article-title":"Impact of implementing a bendamustine-based conditioning regimen on outcomes of autologous stem cell transplantation in lymphoma while novel cellular therapies emerge","volume":"29","author":"Lachance","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.18502\/ijhoscr.v17i2.12647","article-title":"Evaluating the efficacy of modified Beeam (Bendamustine, Etoposide, Cytarabine, Melphalan) regimen as conditioning for autologous stem cell transplantation in relapsed or refractory lymphoma: An experience from two centers of a developing country","volume":"17","author":"Ramzi","year":"2023","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1403019","article-title":"A retrospective, matched paired analysis comparing bendamustine containing Beeam versus Beam conditioning regimen: Results from a single center experience","volume":"59","author":"Saleh","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14320","article-title":"Reduced intensity conditioning prior autologous stem cell transplantation in elderly Dlbcl patients","volume":"114","author":"Strussmann","year":"2025","journal-title":"Eur J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0783-y","article-title":"Bendamustine-Eam versus Beam regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: A multicenter retrospective study from Lymphoma Study Association (Lysa) centers","volume":"55","author":"Hueso","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1186\/s12885-024-12694-9","article-title":"Clinical and safety outcomes of Beeam (Bendamustine, Etoposide, Cytarabine, Melphalan) versus Cem (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation","volume":"24","author":"Eltelbanei","year":"2024","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-351924","article-title":"Beeam (Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients","volume":"118","author":"Visani","year":"2011","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-596668","article-title":"Bendamustine, Etoposide, Cytarabine, Melphalan, and autologous stem cell rescue produce a 72% 3-year Pfs in resistant lymphoma","volume":"124","author":"Visani","year":"2014","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jtct.2022.05.022","article-title":"High-dose bendamustine, etoposide, cytarabine, and melphalan (Beeam) conditioning before autologous transplantation for patients with multiple myeloma","volume":"28","author":"Solomon","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2203790","article-title":"Single-center retrospective study assessing the efficacy and safety of Beeam (Bendamustine, Etoposide, Cytarabine, Melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation","volume":"64","author":"Plante","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0328-9","article-title":"High-dose Benda-Eam versus Beam in patients with relapsed\/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation","volume":"54","author":"Tsang","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25077","article-title":"Bendamustine-based conditioning prior to autologous stem cell transplantation (Asct): Results of a French multicenter study of 474 patients from Lymphoma Study Association (Lysa) centers","volume":"93","author":"Chantepie","year":"2018","journal-title":"Am J Hematol"},{"key":"B16","article-title":"Efficacy and safety of Beeam, a conditioning regimen for autologous stem cell transplantation in Malignant lymphoma","volume":"33","author":"Gou","year":"2025","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.5114\/wo.2024.141794","article-title":"Evaluation of outcome and safety profile in high-dose Beam and Benda-Eam chemotherapy with subsequent autologous stem cell transplantation in lymphoma patients","volume":"28","author":"Krawiec","year":"2024","journal-title":"Contemp Oncol (Pozn)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102318","article-title":"Bendaeam versus Beam as conditioning regimen for Asct in patients with relapsed lymphoma (Beb): A multicentre, randomised, phase 2 trial","volume":"66","author":"Keil","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12893-018-0454-8","article-title":"Advanced hemostasis in axillary lymph node dissection for locally advanced breast cancer: New technology devices compared in the prevention of seroma formation","volume":"18","author":"Gambardella","year":"2019","journal-title":"BMC Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03206-5","article-title":"Seom-Gotel clinical guidelines on diffuse large B cell lymphoma (2022)","volume":"25","author":"Guma","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0057","article-title":"Nccn Guidelines\u00ae insights: B-cell lymphomas, version 6.2023","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264106","article-title":"Application of the Lugano classification for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Prolog Consensus Initiative (Part 1-Clinical)","volume":"64","author":"Ricard","year":"2023","journal-title":"J Nucl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (Ctcae - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1003.e1","DOI":"10.1016\/j.jtct.2024.07.025","article-title":"Early toxicity and efficacy of four different conditioning regimens for autologous hematopoietic cell transplantation in patients with lymphoma: Impact of drug shortages in a resource-constrained country","volume":"30","author":"Carranza","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/bjh.15713","article-title":"Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: A phase 2 study from the Geltamo group","volume":"184","author":"Redondo","year":"2019","journal-title":"Br J Haematol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"14071","DOI":"10.1038\/s41598-021-93516-x","article-title":"Beeam conditioning regimen is a safe, efficacious and economical alternative to Beam chemotherapy","volume":"11","author":"Hahn","year":"2021","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2020.11.003","article-title":"Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study","volume":"14","author":"AlJohani","year":"2021","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.19746\/j.cnki.issn.1009-2137.2021.04.022","article-title":"Clinical efficacy of autologous hematopoietic stem cell transplantation for patients with diffuse large B-cell lymphoma","volume":"29","author":"Fan","year":"2021","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279426","article-title":"Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: A multicenter Geltamo\/Fil study","volume":"107","author":"Garcia-Sancho","year":"2022","journal-title":"Haematologica"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13102","article-title":"High-dose bendamustine-Eam followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity","volume":"101","author":"Noesslinger","year":"2018","journal-title":"Eur J Haematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279999","article-title":"Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: Evidence of durable benefit","volume":"107","author":"Mei","year":"2022","journal-title":"Haematologica"},{"key":"B33","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jtct.2021.02.009","article-title":"Impact of cell of origin classification on survival outcomes after autologous transplantation in relapsed\/refractory diffuse large B cell lymphoma","volume":"27","author":"Joseph","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05813-w","article-title":"Beeam vs. Beam: Evaluating conditioning regimens for autologous stem cell transplantation in patients with relapsed or refractory Dlbcl","volume":"103","author":"Wang","year":"2024","journal-title":"Ann Hematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04043-0","article-title":"Upfront autologous hematopoietic stem cell transplantation for high-risk patients with double-expressor diffuse large B cell lymphoma","volume":"99","author":"Kim","year":"2020","journal-title":"Ann Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1730912\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:31:27Z","timestamp":1785745887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1730912\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":35,"alternative-id":["10.3389\/fonc.2026.1730912"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1730912","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"article-number":"1730912"}}